News

Alpha Tau advances Alpha DaRT for recurrent cutaneous squamous cell carcinoma, offering a novel, localized treatment option with minimal toxicity.

Zasocitinib emerges as a highly selective and potent allosteric TYK2 inhibitor, showing promise for treating immune-mediated inflammatory diseases.

Dupilumab shows significant effectiveness and safety in treating severe AD in children aged 6 months to 5 years, enhancing quality of life.

New research confirms how skin tension line-oriented grafting enhances cosmetic outcomes in basal cell carcinoma surgery, improving aesthetics without compromising quality of life.

Oruka Therapeutics reveals promising interim results for ORKA-002 and launches the EVERLAST-B trial for ORKA-001, targeting chronic skin diseases.

Adelle Walker explores the future of aesthetics as personalized, holistic approaches and regenerative treatments, particularly in younger patients, reshape trends in 2026.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on phase 3 data of envudeucitinib for psoriasis, a combination treatment of ixekizumab and tirzepatide for PsA, a BLA pathway for sonelokimab in HS, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Discover how vitamin D receptor signaling influences hair follicle health and alopecia, revealing new therapeutic possibilities for hair loss management.

Discover how trifarotene could enhance acne treatment in Malaysia, addressing both facial and truncal acne while improving hyperpigmentation and scarring.

Navigator Medicines advances NAV-240 and NAV-242, targeting dual inflammation pathways for hidradenitis suppurativa in upcoming clinical trials.

A new study evaluates the quality and reliability of melasma posts on TikTok and Bilibili, highlighting gaps in treatment information and educational value.

Research reveals that structural changes in neoantigens enhance tumor rejection, offering new insights for personalized cancer immunotherapies.

Results from the TOGETHER-PsA trial reveal that combining ixekizumab and tirzepatide significantly improves outcomes for patients with psoriatic arthritis (PsA) and obesity.

MoonLake Immunotherapeutics shares promising updates on sonelokimab's efficacy for hidradenitis suppurativa.

CSU significantly impacts family quality of life, revealing the need for comprehensive care and support for both patients and their caregivers.

Jasper Therapeutics reveals promising briquilimab data, showcasing rapid disease control and safety in chronic spontaneous urticaria and chronic inducible urticaria.

Johnson & Johnson reveals JNJ-95475939's early termination due to insufficient efficacy in treating moderate-to-severe atopic dermatitis.

Verrica Pharmaceuticals initiates phase 3 trials for VP-102, aiming to provide an effective treatment for common warts, addressing significant unmet needs.

Explore the effectiveness of herbal acne therapies versus social media trends, revealing both promising treatments and potential misinformation risks.

Apogee Therapeutics reveals promising phase 1b trial results for zumilokibart, highlighting its potential as a durable treatment for atopic dermatitis.

Johnson & Johnson's nipocalimab shows promise in reducing systemic lupus erythematosus activity, paving the way for a phase 3 development program.

Legacy Healthcare has advanced Cinainu into phase 3 study for alopecia areata, offering hope for effective, safe treatment without immunosuppression.

Expert consensus clarifies systemic corticosteroid use in atopic dermatitis, emphasizing risks and advocating for advanced therapies for better patient outcomes.

This review of the latest dermatologic studies includes insights on dupilumab-associated rosacea, the prevalence of young adult acne, psoriasis patients with acute coronary syndrome, and more.

Explore how precision dermatology leverages immune pathways to enhance treatment for inflammatory skin diseases.

At the Dermatology Times Horizons in Advanced Practice meeting in Tampa, Florida, conference chair Lakshi Aldredge, MSN, ANP-BC, DCNP, focused a discussion on efficacy data for adalimumab, secukinumab, and bimekizumab.

Envudeucitinib shows promising results as a new oral therapy for psoriasis, achieving high skin clearance rates and rapid symptom improvement in clinical trials.